Funding for this research was provided by:
Canadian Institutes of Health Research (FDN 143266)
Received: 21 September 2017
Accepted: 1 March 2018
First Online: 15 March 2018
: KT is a health economist, and SM, DM, and AS are mathematical modelers with expertise in transmission dynamic models. HK is an undergraduate student in mathematics. NM is an epidemiologist. DT and SB are HIV epidemiologists with expertise in PrEP implementation science. BS is an information specialist.
: Not applicable. The manuscript does not report on or involved the use of any animal or human data or tissue.
: Not applicable. The manuscript does not contain data from any individual person.
: The following authors declare that they have no competing interests: KT, HK, NM, DM, SB, AS, and SM. SB is a Section Editor and SM is an Associate Editor for BMC Infectious Diseases. BS is an independent information specialist and was paid for her work on this project. DT received research grants (in-kind supply of study drug) from Gilead and is a site principal investigator for a Gilead-sponsored clinical trial.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.